ATE531734T1 - Antikörper gegen p-selectin-glycoproteinliganden 1 (psgl-1) zur behandlung allergischer erkrankungen - Google Patents

Antikörper gegen p-selectin-glycoproteinliganden 1 (psgl-1) zur behandlung allergischer erkrankungen

Info

Publication number: ATE531734T1
Authority: AT; Austria
Prior art keywords: cell; psgl; antibodies; treatment; selectin glycoprotein
Prior art date: 2001-08-03

Application number

AT08012718T

Other languages

English (en)

Inventor

Lin Rong-Hwa

Wu Chung-Hsiun

Hsu Pei-Ling

Original Assignee

Abgenomics Cooeperatief U A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-03

Filing date

2002-03-13

Publication date

2011-11-15

2002-03-13 Application filed by Abgenomics Cooeperatief U A filed Critical Abgenomics Cooeperatief U A

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE531734T1 publication Critical patent/ATE531734T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)

AT08012718T 2001-08-03 2002-03-13 Antikörper gegen p-selectin-glycoproteinliganden 1 (psgl-1) zur behandlung allergischer erkrankungen ATE531734T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31019601P	2001-08-03	2001-08-03
US10/051,497 US7744888B2 (en)	2001-08-03	2002-01-18	Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies

Publications (1)

Publication Number	Publication Date
ATE531734T1 true ATE531734T1 (de)	2011-11-15

Family

ID=26729479

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT08012718T ATE531734T1 (de)	2001-08-03	2002-03-13	Antikörper gegen p-selectin-glycoproteinliganden 1 (psgl-1) zur behandlung allergischer erkrankungen
AT02733839T ATE411045T1 (de)	2001-08-03	2002-03-13	Modulatoren des p-selectin-glycoprotein-liganden 1

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT02733839T ATE411045T1 (de)	2001-08-03	2002-03-13	Modulatoren des p-selectin-glycoprotein-liganden 1

Country Status (19)

Country	Link
US (3)	US7744888B2 (de)
EP (2)	EP1411982B1 (de)
JP (3)	JP4815101B2 (de)
KR (1)	KR100850731B1 (de)
CN (2)	CN1304051C (de)
AT (2)	ATE531734T1 (de)
AU (1)	AU2002305041B2 (de)
CA (1)	CA2428822C (de)
CY (2)	CY1108701T1 (de)
DE (1)	DE60229394D1 (de)
DK (2)	DK1985634T3 (de)
ES (2)	ES2316569T3 (de)
IL (4)	IL160168A0 (de)
MX (1)	MXPA04001047A (de)
NO (2)	NO333456B1 (de)
NZ (1)	NZ531199A (de)
PT (2)	PT1411982E (de)
TW (1)	TWI327070B (de)
WO (1)	WO2003013603A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040116333A1 (en) *	2001-08-03	2004-06-17	Rong-Hwa Lin	Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en)	2001-08-03	2010-06-29	Abgenomics Cooperatief U.A.	Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
EP1663290A4 (de) *	2003-09-15	2009-07-01	Abgenomics Corp	Modulatoren des p-selectin-glycoprotein-liganden 1
US7459523B2 (en) *	2003-11-12	2008-12-02	Wisconsin Alumni Research Foundation	Equine P-selectin glycoprotein ligand-1 and uses thereof
AU2012201999C1 (en) *	2004-05-10	2016-05-12	Abgenomics Cooperatief U.A.	Antibodies
MY148646A (en) *	2004-05-10	2013-05-15	Abgenomics Cooperatief Ua	Anti-psgl-1 antibodies
BRPI0510561A (pt) *	2004-05-11	2007-11-20	Abgenomics Corp	epìtopos que induzem morte de célula t
WO2007033959A2 (en) *	2005-09-19	2007-03-29	Vib Vzw	Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
WO2007067984A2 (en) *	2005-12-09	2007-06-14	Wyeth	Neutralizing antibodies against primate psgl-1 and uses therefor
AU2009246166B2 (en) *	2008-05-15	2014-09-18	Tetherex Pharmaceuticals Corporation	Anti-PSGL-1 antibodies and methods of identification and use
ES2387156B1 (es) *	2010-12-01	2013-07-04	Universidad Autónoma de Madrid	Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
EP2718325A4 (de)	2011-06-13	2015-03-11	ABGENOMICS COöPERATIEF U A	Anti-psgl-1 antikörper und verwendungen davon
EP4079324A1 (de) *	2014-07-08	2022-10-26	Sanford-Burnham Medical Research Institute	Psgl-1-modulatoren und verwendungen davon
WO2017120534A1 (en)	2016-01-08	2017-07-13	Bioalliance C.V.	Tetravalent anti-psgl-1 antibodies and uses thereof
US20170241415A1 (en) *	2016-02-19	2017-08-24	Muzan, Inc.	Sanitary check valve
KR20250159733A (ko)	2017-01-11	2025-11-11	브리스톨-마이어스 스큅 컴퍼니	Psgl-1 길항제 및 그의 용도
PE20250933A1 (es)	2017-03-14	2025-04-02	Five Prime Therapeutics Inc	Anticuerpos de union a vista a ph acido
SG11202008593PA (en)	2018-03-21	2020-10-29	Five Prime Therapeutics Inc	ANTIBODIES BINDING TO VISTA AT ACIDIC pH
AU2019301120A1 (en)	2018-07-11	2021-02-25	Bristol-Myers Squibb Company	Antibodies binding to VISTA at acidic pH
KR20250024129A (ko)	2018-07-20	2025-02-18	피에르 파브르 메디카먼트	Vista의 수용체
CN114158275A (zh) *	2019-05-03	2022-03-08	香港大学	腹膜转移细胞的检测和分离方法
KR20220042055A (ko) *	2019-06-04	2022-04-04	베르조 테라퓨틱스, 아이엔씨.	골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도
WO2025168211A1 (en) *	2023-02-10	2025-08-14	Novo Nordisk A/S	P-selectin peptide ligands

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2002A (en) *		1841-03-12		Tor and planter for plowing
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4704692A (en)	1986-09-02	1987-11-03	Ladner Robert C	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5464778A (en) *	1989-03-08	1995-11-07	Board Of Regents Of The University Of Oklahoma	Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) *	1989-03-08	1995-01-03	Board Of Regents Of The University Of Oklahoma	Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) *	1989-05-31	1997-11-25	Glaxo Wellcome Inc.	Monoclonal antibodies for inducing tolerance
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es)	1990-08-29	2006-02-16	Genpharm International, Inc.	Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5709859A (en) *	1991-01-24	1998-01-20	Bristol-Myers Squibb Company	Mixed specificity fusion proteins
US6124267A (en) *	1991-02-05	2000-09-26	Southpac Trust Internationals, Inc.	O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) *	1991-02-05	2001-10-30	The Board Of Regents Of The University Of Oklahoma	Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) *	1991-05-06	1999-10-26	The Regents Of The University Of California	Assays for inhibitors of leukocyte adhesion
US5843707A (en) *	1992-10-23	1998-12-01	Genetics Institute, Inc.	Nucleic acid encoding a novel P-selectin ligand protein
WO1994014836A1 (en) *	1992-12-18	1994-07-07	Centocor, Inc.	Peptide inhibitors of selectin binding
DE69415154T2 (de) *	1993-01-25	1999-07-29	Dana-Farber Cancer Institute, Inc., Boston, Mass.	Chimäre selektine erhältlich durch domänenaustauch und ihre verwendungen
WO1995014787A1 (en) *	1993-11-22	1995-06-01	Centocor, Inc.	Peptide inhibitors of selecting binding
US5686426A (en) *	1994-11-17	1997-11-11	Bristol-Myers Squibb Company	Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
DE69630307T2 (de)	1995-08-03	2004-07-15	The Board Of Regents Of The University Of Oklahoma, Norman	O-glycaninhibitoren von selectinvermittelten entzüngen
JPH09227410A (ja)	1996-02-21	1997-09-02	Sumitomo Pharmaceut Co Ltd	臓器移植拒絶反応の抑制剤
WO1999043353A2 (en) *	1998-02-26	1999-09-02	Boehringer Ingelheim Pharmaceuticals, Inc.	Combination anti-selectin and immunosuppressant therapy
CN1342085A (zh)	1998-10-30	2002-03-27	遗传研究所有限公司	通过p－选择素配体(psgl)拮抗剂抑制细胞素t细胞的分化
US20040002450A1 (en) *	2000-12-29	2004-01-01	Janette Lazarovits	Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
PL366223A1 (en)	2000-12-29	2005-01-24	Bio-Technology General Corp.	Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) *	2000-12-29	2004-01-01	Avigdor Levanon	Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040116333A1 (en) *	2001-08-03	2004-06-17	Rong-Hwa Lin	Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) *	2001-08-03	2010-06-29	Abgenomics Cooperatief U.A.	Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20050152906A1 (en) *	2003-06-30	2005-07-14	Avigdor Levanon	Specific human antibodies
MY148646A (en)	2004-05-10	2013-05-15	Abgenomics Cooperatief Ua	Anti-psgl-1 antibodies
BRPI0510561A (pt)	2004-05-11	2007-11-20	Abgenomics Corp	epìtopos que induzem morte de célula t
EP2718325A4 (de)	2011-06-13	2015-03-11	ABGENOMICS COöPERATIEF U A	Anti-psgl-1 antikörper und verwendungen davon

2002
- 2002-01-18 US US10/051,497 patent/US7744888B2/en not_active Expired - Fee Related
- 2002-03-13 NZ NZ531199A patent/NZ531199A/en not_active IP Right Cessation
- 2002-03-13 DK DK08012718.6T patent/DK1985634T3/da active
- 2002-03-13 ES ES02733839T patent/ES2316569T3/es not_active Expired - Lifetime
- 2002-03-13 KR KR1020047001711A patent/KR100850731B1/ko not_active Expired - Fee Related
- 2002-03-13 DE DE60229394T patent/DE60229394D1/de not_active Expired - Lifetime
- 2002-03-13 AT AT08012718T patent/ATE531734T1/de active
- 2002-03-13 CN CNB028029844A patent/CN1304051C/zh not_active Expired - Fee Related
- 2002-03-13 EP EP02733839A patent/EP1411982B1/de not_active Expired - Lifetime
- 2002-03-13 PT PT02733839T patent/PT1411982E/pt unknown
- 2002-03-13 AT AT02733839T patent/ATE411045T1/de active
- 2002-03-13 AU AU2002305041A patent/AU2002305041B2/en not_active Ceased
- 2002-03-13 EP EP08012718A patent/EP1985634B1/de not_active Expired - Lifetime
- 2002-03-13 JP JP2003518607A patent/JP4815101B2/ja not_active Expired - Fee Related
- 2002-03-13 DK DK02733839T patent/DK1411982T3/da active
- 2002-03-13 MX MXPA04001047A patent/MXPA04001047A/es active IP Right Grant
- 2002-03-13 WO PCT/US2002/007498 patent/WO2003013603A1/en not_active Ceased
- 2002-03-13 CN CN200710003904XA patent/CN101045161B/zh not_active Expired - Fee Related
- 2002-03-13 ES ES08012718T patent/ES2376948T3/es not_active Expired - Lifetime
- 2002-03-13 IL IL16016802A patent/IL160168A0/xx active IP Right Grant
- 2002-03-13 CA CA2428822A patent/CA2428822C/en not_active Expired - Lifetime
- 2002-03-13 PT PT08012718T patent/PT1985634E/pt unknown
- 2002-04-10 TW TW091107216A patent/TWI327070B/zh not_active IP Right Cessation
2004
- 2004-02-02 NO NO20040460A patent/NO333456B1/no not_active IP Right Cessation
- 2004-02-02 IL IL160168A patent/IL160168A/en unknown
2008
- 2008-03-07 JP JP2008058501A patent/JP2008260759A/ja not_active Abandoned
2009
- 2009-01-13 CY CY20091100020T patent/CY1108701T1/el unknown
- 2009-06-29 US US12/494,018 patent/US8298540B2/en not_active Expired - Fee Related
2010
- 2010-02-18 IL IL204030A patent/IL204030A/en active IP Right Grant
2011
- 2011-01-11 IL IL210557A patent/IL210557A0/en unknown
2012
- 2012-02-01 CY CY20121100115T patent/CY1112966T1/el unknown
- 2012-02-03 JP JP2012022511A patent/JP2012092144A/ja active Pending
- 2012-09-14 US US13/616,749 patent/US8557579B2/en not_active Expired - Fee Related
2013
- 2013-01-14 NO NO20130069A patent/NO334850B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN101045161A (zh)	2007-10-03
EP1411982A4 (de)	2004-10-06
CN101045161B (zh)	2010-06-16
EP1411982A1 (de)	2004-04-28
HK1124624A1 (en)	2009-07-17
NO333456B1 (no)	2013-06-10
ES2316569T3 (es)	2009-04-16
US8298540B2 (en)	2012-10-30
DK1411982T3 (da)	2009-02-16
EP1411982B1 (de)	2008-10-15
AU2002305041B2 (en)	2005-11-10
JP2008260759A (ja)	2008-10-30
JP2012092144A (ja)	2012-05-17
MXPA04001047A (es)	2005-02-17
CN1473052A (zh)	2004-02-04
IL204030A (en)	2014-11-30
US8557579B2 (en)	2013-10-15
NO20040460L (no)	2004-02-24
JP4815101B2 (ja)	2011-11-16
JP2004521958A (ja)	2004-07-22
IL160168A0 (en)	2004-07-25
WO2003013603A8 (en)	2004-06-10
IL210557A0 (en)	2011-03-31
WO2003013603A1 (en)	2003-02-20
US20030049252A1 (en)	2003-03-13
CN1304051C (zh)	2007-03-14
CY1112966T1 (el)	2016-04-13
PT1985634E (pt)	2012-02-07
EP1985634B1 (de)	2011-11-02
KR20040054670A (ko)	2004-06-25
US7744888B2 (en)	2010-06-29
IL204030A0 (en)	2011-08-01
NZ531199A (en)	2004-11-26
DE60229394D1 (en)	2008-11-27
IL160168A (en)	2011-02-28
CY1108701T1 (el)	2014-04-09
US20130011861A1 (en)	2013-01-10
DK1985634T3 (da)	2012-02-20
ES2376948T3 (es)	2012-03-21
EP1985634A1 (de)	2008-10-29
KR100850731B1 (ko)	2008-08-06
CA2428822A1 (en)	2003-02-20
ATE411045T1 (de)	2008-10-15
TWI327070B (en)	2010-07-11
NO334850B1 (no)	2014-06-16
CA2428822C (en)	2014-10-28
HK1065489A1 (en)	2005-02-25
NO20130069L (no)	2004-02-24
US20090304709A1 (en)	2009-12-10
PT1411982E (pt)	2008-12-24

Publication	Publication Date	Title
CY1112966T1 (el)	2016-04-13	Αντισωμα δεσμευον το γλυκοπρωτεϊνικο προσδεμα 1 της p-σελεκτινης (ρsgl-1) για χρηση στην αγωγη αλλεργικης νοσου
DE60325189D1 (de)	2009-01-22	Wasserfilter
WO2005027831A3 (en)	2005-12-01	Modulators of p-selectin glycoprotein ligand 1
WO2004043361A3 (en)	2007-10-04	Compositions and methods for the treatment of natural killer cell related diseases
ATE483472T1 (de)	2010-10-15	Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
ATE405650T1 (de)	2008-09-15	Produktion von ganzen antikörpern in prokaryontischen zellen
MXPA02000119A (es)	2003-07-21	Elementos mezcladores estaticos apilados.
ATE404196T1 (de)	2008-08-15	Rapamycin und il-10 zur behandlung von autoimmunerkrankungen
ATE440618T1 (de)	2009-09-15	Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
EA200700175A1 (ru)	2007-08-31	Композиции и способы лечения воспалительных заболеваний
ATE474592T1 (de)	2010-08-15	Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz
DE60109826D1 (de)	2005-05-04	Biologischer filter zur reinigung von abgasen
TW200607863A (en)	2006-03-01	Immune modulating compounds from fungi
TW200606177A (en)	2006-02-16	Glycoprotein VI antibodies and methods thereof
ATE439851T1 (de)	2009-09-15	Verwendung probiotischer bakterien zur behandlung von infektionen
EP1501465A4 (de)	2006-04-19	Vektoren mit beiden isoformen von beta-hexosaminidase
DE50108409D1 (de)	2006-01-19	Behandlung von oberflächen zur temporären verbesserung des schmutzablöseverhaltens
ATE442157T1 (de)	2009-09-15	Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
DE60313803D1 (de)	2007-06-21	Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
TW200513262A (en)	2005-04-16	Modulators of P-selectin glycoprotein ligand 1
ATE146967T1 (de)	1997-01-15	Verwendung von ifn-gamma zur behandlung von infektionen bei transplantatenempfängern
EA200600956A1 (ru)	2006-10-27	Молекулы-антагонисты цитокинов
DE502004012196D1 (de)	2011-03-31	Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen
DE602006015373D1 (de)	2010-08-19	Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten
ATE373477T1 (de)	2007-10-15	Cci-779 zur behandlung von mantelzelllymphom